FIBERGRAFT BG Morsels
Commercial- Indications
- Bone defects, Traumatic bone injury
Company intelligence / Profile preview
Prosidyan
New Providence, New Jersey, United Statesprweb.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Commercial
01
Overview
Prosidyan’s FIBERGRAFT line of synthetic bioactive bone graft substitutes has demonstrated high clinical efficacy, achieving a 96.3% fusion rate in multi-center clinical studies for posterolateral spinal fusion with no device-related complications or adverse events. Products are FDA-cleared and have been used successfully in thousands of patients across the U.S.
- Therapeutic areas
- OtherRheumatology
- Modalities
- DeviceSynthetic bone graft substitute (bioactive glass fiber-based)
- Industry
- Implantable Medical Devices
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Joint collaboration and license agreements to access new intellectual property for next-generation synthetic bone graft platforms; specific partners not named publicly
Beyond the preview
Go deeper on Prosidyan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prosidyan.